Study on Aprepitant for HIV Treatment
Author Information
Author(s): Pablo Tebas, Florin Tuluc, Jeffrey S. Barrett, Wayne Wagner, Deborah Kim, Huaquing Zhao, René Gonin, James Korelitz, Steven D. Douglas, Andrew D. Badley
Primary Institution: University of Pennsylvania
Hypothesis
Does aprepitant, a neurokinin-1 receptor antagonist, have safety and antiviral activity in HIV-infected adults not receiving antiretroviral therapy?
Conclusion
Aprepitant showed biological activity but no significant antiviral activity in HIV-infected adults.
Supporting Evidence
- Aprepitant was safe in HIV-infected patients not receiving antiretroviral therapy.
- Adverse events were more common in the aprepitant-treated groups.
- No significant changes in HIV RNA viral load were observed.
Takeaway
This study tested a drug called aprepitant to see if it could help people with HIV. It was safe but didn't really help lower the virus levels.
Methodology
A phase IB randomized, placebo-controlled, double-masked study with HIV-infected adults not on antiretroviral therapy, receiving aprepitant or placebo for 14 days.
Potential Biases
Potential bias due to the small number of participants and the nature of the study design.
Limitations
The study had a small sample size and a short duration of treatment.
Participant Demographics
63% male, 37% white, mean age 43 years.
Statistical Information
P-Value
p=0.042
Confidence Interval
95% CI for changes in viral load: Low - (−0.24,+0.20), High - (−0.21,+0.10), PL - (−0.08,+0.16)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website